29/06/2020
Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan...
10/06/2020
F2G’s olorofim receives both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP designation for multiple fungal infections F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections,...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments